When should ECMO be started and stopped? This month’s Ethics Talk explores ethical challenges of ECMO use in end-of-life care.

Sterling Johnson joins Ethics Talk to discuss his article, coauthored with Dr Kimberly L. Sue: "Drawing on Black and Queer Communities’ Harm Reduction Histories to Improve Overdose Prevention Strategies and Policies.”

Legal inconsistencies and variation in end-of-life options generate disparities in care for unrepresented patients.

The AMA Code of Medical Ethics discusses situations in which a surrogate is needed but not available to make health care decisions for a patient.

Many nonphysician health care practitioners are looking to expand their scope of practice.

Lack of ethical, legal, and clinical consensus about best practice sometimes combines with a poor clinical evidence base.

Long-term care facilities should assess residents for capacity to consent to sexual activity and be prepared to accommodate sexual intimacy.

PSOs are not required to share their data, which limits the ability to achieve a much-needed national perspective. Regardless, the are a step in the right direction.

Black and queer community-based harm reduction practices can help guide development and implementation of anti-overdose interventions.

Decision aids could help clinicians know when to request ethics consultation or re-evaluate blood product usage in a specific patient care situation.